Here, Lydia Scarfò, MD, of Vita-Salute San Raffaele University, Milan, Italy, gives an interesting insight about the possible reasons behind…
Browsing: Chronic Lymphocytic Leukemia
Patients with advanced chronic lymphocytic leukemia (CLL) don’t respond well to chimeric antigen receptor (CAR) T-cell therapy. In this interview,…
Chris Fegan, MB, MD, FRCP, FRCPath, from Cardiff University, Cardiff, UK, touches on several of the national and international cohort…
Telomere erosion and fusion play an important role in the pathology of many common human malignancies, including chronic lymphocytic leukemia…
To determine the true impact of ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL) within a population-based setting rather…
Venetoclax is making headlines due to its effectiveness against many hematological cancers. In this video, Giovanni Martinelli, MD, of the…
After presenting the initial results of a study investigating the efficacy of ibrutinib for chronic lymphocytic leukemia (CLL) within a…
Since its approval in late 2014, ibrutinib has primarily been studied in clinical trials, such as RESONATE (NCT01578707), and in…
Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany discusses the results of the recent Phase III CLL11 trial (NCT01998880). The…
Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany, talks to us about exciting new data for the venetoclax and rituximab…
Treating young patients with chronic lymphocytic leukemia (CLL) poses a unique set of challenges because treatment has to be effective…
Chronic lymphocytic leukemia (CLL) treatment is experiencing a shift away from chemotherapy in favor of novel agents. FCR chemotherapy, however,…
There has been a multitude of novel, exciting therapies within the field of chronic lymphocytic leukemia (CLL), explains Stephen Devereux,…
New genetic sequencing techniques could yield profound insights into disease progression in chronic lymphocytic leukemia (CLL). Niamh Appleby, MB, BAO,…
Speaking from the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Niamh Appleby, MB, BAO,…
The drive to find treatment options for chronic lymphocytic leukemia (CLL) with lower toxicities means clinicians are relying less and…
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, presented preliminary data from the Phase II CAPTIVATE trial (NCT02910583)…
Chronic lymphocytic leukemia (CLL) is usually fairly non-aggressive; however, there remain certain patients who have a rapidly progressing disease and…
The management of relapsed chronic lymphocytic leukemia (CLL) is a complex and difficult issue. We interviewed William Wierda, MD, PhD,…
Biomarker screening has become an essential component of constructing treatment plans in chronic lymphocytic leukemia (CLL). In this video, recorded…
Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research.…
There has been an influx of novel agents in the field of chronic lymphocytic leukemia (CLL) in recent years. These…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, John Seymour, MBBS, FRACP,…
BCL-2 inhibitors like ibrutinib and venetoclax have been used in the treatment of lymphoproliferative disorders like chronic lymphocytic leukemia (CLL)…
MOR208 is an anti-CD19 monoclonal antibody that has been effective in treating a range of lymphomas, including diffuse large B-cell…
Measurable residual disease (MRD) is becoming increasingly important as a prognostic indicator in a wide variety of hematological malignancies. We…
The development of novel agents for treating chronic lymphocytic leukemia (CLL) has transformed the field in recent years. In this…
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, is the president of the European Research Initiative on…
The use of tyrosine kinase inhibitors (TKIs) in chronic lymphocytic leukemia (CLL) is expanding. In this video, recorded at the…
The CLL11 trial (NCT01998880) compared chlorambucil monotherapy with combination therapies of chlorambucil and anti-CD20 antibodies rituximab or obinutuzumab for chronic…
Novel agent combination therapies are coming to the forefront of chronic lymphocytic leukemia (CLL) research. Here, William Wierda, MD, PhD,…
MURANO (NCT02005471) is a Phase III randomized trial comparing the efficacy of venetoclax plus rituximab vs. standard chemoimmunotherapy of bendamustine…
Lymphoproliferative disorders can be characterized by a certain set of pathogenic events. These include the upregulation of anti-apoptotic pathways guided…
In chronic lymphocytic leukemia (CLL), treatment is often delayed because patients develop infections. Florence Cymbalista, PhD, from the Hôpital Avicenne,…
The CLARITY study (ISCRTN13751862) is the first clinical trial looking at the combination of venetoclax and ibrutinib for treating relapsed/refractory…
While the treatment landscape of chronic lymphocytic lymphoma (CLL) has been exciting with many breakthrough therapies, there are still key…
It is important that current techniques for the monitoring of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) are…
Minimal residual disease (MRD) is the small number of leukemic cells that remain after treatment and there are no signs…
In this whiteboard video, Dr. John N. Allan of Weill Cornell Medicine discusses the mechanisms of action of anti-apoptotic BCL2…
In this whiteboard video, Dr. John N. Allan of Weill Cornell Medicine discusses the mechanisms of action of anti-CD20 agents.…
In this whiteboard video, Dr. John N. Allan of Weill Cornell Medicine discusses the mechanisms of action of BRC signaling…
Robert Kreitman, MD, from the National Cancer Institute, Bethesda, MD, discusses a clinical trial using the recombinant immunotoxin, moxetumomab pasudotox,…
There are a growing number of investigations of novel combination therapies for chronic lymphocytic leukemia (CLL). These are discussed in…
The MURANO trial (NCT02005471) compared the benefit of venetoclax plus rituximab vs. bendamustine plus rituximab in chronic lymphocytic leukemia (CLL),…
Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from Leeds Teaching Hospital NHS Trust, Leeds, UK, provides an insight into the use…
In this interview, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from Leeds Teaching Hospital NHS Trust, Leeds, UK, details the importance…
The multitude of novel therapies in the field of chronic lymphocytic leukemia (CLL) paves the way for exciting future possibilities.…
Promising novel therapies are on the horizon within the field of chronic lymphocytic leukemia (CLL). Here, Jennifer Woyach, MD, of…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Anthony Mato, MD, MSCE, from…
Intolerance is the most common reason for discontinuing PI3K or BTK inhibitor drugs used for the treatment of chronic lymphocytic…